Markets:

Overview

News

Currencies

International

Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

31.02 +0.66 (+2.19%)

Streaming Delayed Price Updated: 11:02 AM EST, Dec 22, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

31 32 Next >

Direct Relief, the National Association of Free and Charitable Clinics and Teva Pharmaceuticals Partner to Advance Access to Behavioral Health Services

June 08, 2022

From Teva Pharmaceutical Industries Limited

Via Business Wire

Golden Cross Appears Before Teva Pharmaceutical Indus Investors ↗

May 27, 2022

If history is any guide, there may be good fortune ahead for shares of Teva Pharmaceutical Indus (NYSE:TEVA). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be...

Via Benzinga

Teva, Allergan Settle Opioid Lawsuit With West Virginia ↗

May 25, 2022

U.S. affiliate of Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has reached an agreement with the Attorney General of West Virginia that settles the state's opioid-related claims.

Via Benzinga

Teva Reaches Agreement With West Virginia to Settle the State’s Opioid-Related Claims

May 25, 2022

From Teva Pharmaceutical Industries Limited

Via Business Wire

Why Generic Drugs Giant Teva Pharmaceutical Just Cut Its 2022 Outlook ↗

May 03, 2022

Foreign exchange rates are weighing heavily on sales, according to the firm's CEO.

Via Investor's Business Daily

FDA Rejects Teva - MedinCell's Schizophrenia Candidate ↗

April 20, 2022

Via Benzinga

Teva Presents New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at 2022 American Psychiatric Association Annual Meeting

May 23, 2022

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva Pharmaceutical Shares Real-World Data Of ProAir Digihaler In Asthma Patients ↗

May 17, 2022

Via Benzinga

BofA Upgrades Teva Pharmaceutical On Possible Opioid Deal ↗

May 17, 2022

Prospects of a global opioid deal getting done in 2022 suggest a “potential path to upside” for Teva Pharmaceutical Industries Ltd.’s (NYSE: TEVA) stock, according to BofA Securities.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 17, 2022 ↗

May 17, 2022

Via Benzinga

United Kingdom first to grant licence for Teva’s ophthalmology biosimilar Ongavia (ranibizumab)▼

May 17, 2022

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva to Present Latest Research From Neurology Portfolio at the 2022 American Psychiatric Association Annual Meeting

May 17, 2022

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva Announces New Findings Highlighting Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder to Address Asthma Treatment Challenges

May 17, 2022

From Teva Pharmaceutical Industries Limited

Via Business Wire

4 Analysts Have This to Say About Teva Pharmaceutical Indus ↗

May 12, 2022

Over the past 3 months, 4 analysts have published their opinion on Teva Pharmaceutical Indus (NYSE:TEVA) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

Teva to Present Findings on Short-Acting Beta Agonist (SABA) Use in Asthma Patients and the Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder to Help Inform Treatment Decisions at American Thoracic Society 2022 Annual Meeting

May 12, 2022

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva, Allergan Ready To Pay $5B To Settle Lawsuits Related To Opioid Painkillers: Bloomberg ↗

May 11, 2022

Via Benzinga

Teva Publishes 2021 ESG Progress Report, Showcasing Further Integration of ESG Into Business, Robust Targets and Strengthened ESG Governance Structure

May 10, 2022

From Teva Pharmaceutical Industries Limited

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2022 ↗

May 04, 2022

Upgrades

Via Benzinga

Teva Posts Mixed Q1 Earnings, Cuts FY22 Sales Guidance Citing Copaxone Competition, Yet Shares Rise ↗

May 03, 2022

Via Benzinga

The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs ↗

May 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Recap: Teva Pharmaceutical Q1 Earnings ↗

May 03, 2022

Teva Pharmaceutical Indus (NYSE:TEVA) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Teva Reports First Quarter 2022 Financial Results

May 03, 2022

From Teva Pharmaceutical Industries Limited

Via Business Wire

The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More ↗

May 02, 2022

Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks...

Via Benzinga

Earnings Scheduled For May 3, 2022 ↗

May 03, 2022

Companies Reporting Before The Bell • Kiniksa Pharmaceuticals (NASDAQ:KNSA) is projected to report earnings for its first quarter.

Via Benzinga

Teva Announces Settlement with Lupin Resolving AUSTEDO® (deutetrabenazine) Patent Dispute

May 02, 2022

From Teva Pharmaceutical Industries Limited

Via Business Wire

San Francisco To Start Opioid Epidemic Trial Against Teva, Walgreen: Reuters ↗

April 25, 2022

Via Benzinga

JNJ, McKesson, Endo Settle $275M Opioid Claims With Alabama: Reuters ↗

April 20, 2022

Via Benzinga

The Daily Biotech Pulse: Windtree Jumps On Istaroxime Data, Arcturus' COVID-19 Vaccine Trial Data, FDA Rejects Teva's Schizophrenia Med, Otonomy Aces Hearing Loss Study ↗

April 20, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Teva and MedinCell Receive Complete Response Letter for TV-46000/mdc-IRM

April 19, 2022

From Teva Pharmaceutical Industries Limited

Via Business Wire

What Were Your Best And Worst Stock Buys? What Does The Zinger Nation Think? ↗

April 06, 2022

Admitting to success is a lot easier than failure and when it comes to stocks, not only is there money involved, but also questioning your — or your advisor's — judgment. And then there is the advice...

Via Benzinga

< Previous 1 2

...

19 20 21 22 23 24 25 26 27

...

31 32 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.